Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag
This article was originally published in The Gray Sheet
Executive Summary
Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart